Legal Representation
Attorney
Rosemary S. Tarlton
USPTO Deadlines
Application History
18 events| Date | Code | Type | Description |
|---|---|---|---|
| Mar 23, 2009 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Mar 23, 2009 | MAB6 | O | ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED |
| Jul 29, 2008 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Jul 29, 2008 | EXT1 | S | SOU EXTENSION 1 FILED |
| Jul 29, 2008 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Feb 19, 2008 | NOAM | O | NOA MAILED - SOU REQUIRED FROM APPLICANT |
| Nov 27, 2007 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Nov 7, 2007 | NPUB | O | NOTICE OF PUBLICATION |
| Oct 22, 2007 | ALIE | A | ASSIGNED TO LIE |
| Oct 22, 2007 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Sep 20, 2007 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Sep 19, 2007 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Sep 18, 2007 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Sep 18, 2007 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jun 6, 2007 | CNRT | F | NON-FINAL ACTION MAILED |
| Jun 5, 2007 | CNRT | R | NON-FINAL ACTION WRITTEN |
| May 30, 2007 | DOCK | D | ASSIGNED TO EXAMINER |
| Feb 15, 2007 | NWAP | I | NEW APPLICATION ENTERED |
Detailed Classifications
Class 005
Pharmaceuticals, namely, pharmaceuticals for the treatment of central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular diseases, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; implantable delivery systems comprised of sustainable release drugs for treatment for central nervous disorders, cancer, hematological disorders, endocrine disorders, metabolic disorders, inflammatory disorders, gastrointestinal disorders, liver disease, heart disorders, lung and bronchial disease, blood cardiovascular diseases, circulatory system disease, intestinal disorders, bone disease, autoimmune disorders and disorders of the immune systems, infectious disease and enzyme deficiency disease; and anti-cancer vaccines
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"MEDICINE"
USPTO Documents
Loading USPTO documents...